– BELGIUM, Ghent – Agomab Therapeutics NV today announced the appointment of David Epstein to its Board as a Non-Executive Director and Chairman.
“We are very happy to welcome David as Chairman of our Board of Directors. David serves as a role model in the industry and we look forward to working closely with him and leveraging his experience to help bring innovative treatments to patients with fibrotic diseases,” said CEO Tim Knotnerus.
About David Epstein
David Epstein is an industry veteran and most recently served as Seagen’s CEO and as a member of its Board of Directors. Under his leadership, Seagen significantly grew its portfolio of innovative cancer medicines and was acquired for more than $43 billion by Pfizer in December 2023. Before Seagen, he served as Novartis Pharmaceuticals’ CEO. David Epstein has more than 30 years of drug development, deal-making, commercialization, and leadership experience on a global scale. Throughout his career, he has led the development and commercialization of over 30 new molecular entities, including Glivec, Tasigna, Gilenya, Cosentyx, Entresto, and Padcev. He was named by FierceBiotech as one of the “25 most influential people in biopharma”.
“I am very impressed by Agomab’s science and strategy and I look forward to working with Tim and his team in bringing Agomab to the next phase of development and growth,” said David Epstein. “Fibrotic diseases represent a serious unmet medical need and I truly believe Agomab’s approach could represent great strides for patients with Fibrostenosing Crohn’s Disease and Idiopathic Pulmonary Fibrosis, if approved.”
About Agomab
Agomab is focused on achieving disease modification by modulating fibrosis and regeneration in chronic indications such as Fibrostenosing Crohn’s Disease and Idiopathic Pulmonary Fibrosis. We do this by targeting biologically validated pathways – including Transforming Growth Factor β and Hepatocyte Growth Factor – and by applying specialized capabilities in organ-restricted small molecules and high-affinity antibodies. With a differentiated clinical pipeline across several fibrotic disorders, end-to-end research and development capabilities, a proven BD track record, and a strong investor base, Agomab is building a leading biopharma company.
For more https://agomab.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.